SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in March:
To access the live webcasts or subsequent archived recordings of the discussions, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases.
RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com
RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com
Winter Park, Florida--(Newsfile Corp. - February 4, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a…
Now Accepting Nomination Submissions for the Prestigious Annual AwardToronto, Ontario--(Newsfile Corp. - February 4, 2026)…
DRAPER, UTAH / ACCESS Newswire / February 4, 2026 / CenExel, a leading, wholly owned…
BOCA RATON, FL / ACCESS Newswire / February 4, 2026 / GridAI Technologies Corp. (Nasdaq:GRDX),…
Targeting Q1 2026 Launch, Subject to FDA ClearanceKey Highlights:Cartridge & Infusion Set Lots in Production:…
New Market Briefing From Black Book Research Highlights 80% of Surveyed Hospitals Active in EHR…